694 related articles for article (PubMed ID: 10926326)
1. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
2. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
Abramovich CM; Prayson RA
Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
[TBL] [Abstract][Full Text] [Related]
8. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
9. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations].
Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM
Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
13. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
15. Characterization of morphologically benign biologically aggressive meningiomas.
Rao S; Sadiya N; Doraiswami S; Prathiba D
Neurol India; 2009; 57(6):744-8. PubMed ID: 20139503
[TBL] [Abstract][Full Text] [Related]
16. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
19. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas.
Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S
Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191
[TBL] [Abstract][Full Text] [Related]
20. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]